Voyager Therapeutics (VYGR) Cash from Investing Activities (2014 - 2026)

Voyager Therapeutics has reported Cash from Investing Activities for 13 years, with the latest figure at $8.1 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 80.34% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.3 million (up 117.76% YoY) and the FY2025 annual result came in at $125.4 million, up 232.24% from the prior year.
• Cash from Investing Activities eased to $8.1 million in Q1 2026 per VYGR's latest filing, from $47.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $64.4 million in Q3 2024 and troughed at -$158.3 million in Q3 2023.
• A 5-year average of -$6.5 million and a median of $8.1 million in 2026 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities surged 357.45% in 2022, then tumbled 762.93% in 2024.
• Over 5 years, Cash from Investing Activities stood at $14.1 million in 2022, then jumped by 90.75% to $26.8 million in 2023, then slumped by 201.38% to -$27.2 million in 2024, then soared by 274.33% to $47.4 million in 2025, then slumped by 82.92% to $8.1 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $8.1 million, $47.4 million, and $34.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.